Experts are always on the lookout for ASX shares that could produce strong returns. We’re going to look at two names that could outperform the S&P/ASX 200 Index (ASX: XJO).

It’s interesting when one analyst likes a business, it’s very intriguing when multiple analysts think an ASX share is a buy.

Below are two of the most potentially exciting stocks with multiple buy ratings.

Goodman Group (ASX: GMG)

Goodman is the largest property business on the ASX – it develops, owns and manages a global portfolio of industrial properties.

According to the Commsec collation of analyst opinions, there are currently 12 buy ratings, two hold ratings and no sell ratings on the business. There are very few ASX shares that have as much analyst backing as Goodman right now.

Goodman is working on a very impressive development pipeline that could significantly add to its underlying value.

In the quarterly update for the three months to 31 March 2026, Goodman said that its work in progress (WIP) was $14.5 billion, with an annualised production rate of around $6 billion. The yield on cost on the current WIP is 8%.

Data centres under construction represent around 73% of WIP, so the business is looking to benefit from that high demand for new data centre facilities.

The rental performance of its property portfolio continues to perform solidly. Its third-quarter update revealed 4.1% like-for-like net property income (NPI) growth.

Guzman Y Gomez Ltd (ASX: GYG)

Another ASX share with strong backing is Guzman Y Gomez, one of Australia’s largest Mexican food businesses.

At 31 March 2026, the business had 242 locations in Australia (of which 155 were franchise restaurants), 23 locations in Singapore and five in Japan – this represented an increase of at least 14% year over year for each market.

The Commsec collation of analyst opinions shows there are currently 10 buy ratings on the business, with two hold ratings and two sell ratings.

The Guzman Y Gomez share price is much cheaper than it was a year ago – it’s 25% lower. Yet, the company continues to grow strongly. In the third quarter of FY26, Australian network sales grew by 19.7% to $320.4 million, and Asian network sales increased 15% to $21.5 million, with those markets delivering combined comparable sales growth of 6.6%.

The ASX share expects the Australian and Asian divisions to deliver year-over-year growth in underlying operating profit (EBITDA) of approximately 29%.

Over time, the company expects to reach 1,000 Australian restaurants and segment underlying EBITDA as a percentage of network sales of 10%. This could increase the value of the business significantly in the coming years.

The post 2 ASX shares highly recommended to buy: Experts appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares given buy ratings this week
• The best AI stocks on the ASX right now
• 10 of the best ASX shares to buy in FY 2027
• Should you buy property or stocks? Here’s what you need to consider
• 2 ASX shares highly recommended to buy: Experts

Motley Fool contributor Tristan Harrison has positions in Guzman Y Gomez. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group. The Motley Fool Australia has recommended Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Something changed in every Australian worker’s pay packet this week.

From 1 July 2026, the tax rate on income between $18,201 and $45,000 dropped from 16% to 15%. This delivered a tax cut to almost every Australian taxpayer regardless of income level.

The cut is applied automatically through your employer’s payroll. You do not need to do anything to receive it.

The actual dollar amount

The size of the benefit depends on how much of your income falls in the $18,201 to $45,000 bracket.

For someone earning exactly $45,000, the benefit from this round of cuts alone is approximately $268 per year, or around $5.15 per week.

For someone earning above $45,000, the benefit is also $268, since the portion of income taxed at the lower rate also receives this benefit.

However, the government’s total tax cuts since 2024 are larger than this single round.

An average earner on $81,245 will receive $1,978 in total tax cuts in FY27 compared to 2023-24 settings, when all three rounds of legislated tax cuts are combined.

That is $38 per week more in take-home pay than two years ago.

From 1 July 2027, the same bracket rate drops again to 14%, adding an additional maximum of $268 per year in tax savings.

The $1,000 instant tax deduction

Alongside the rate cut, a new $1,000 instant tax deduction for work-related expenses starts this financial year.

Previously, workers could only claim up to $300 in work-related expenses without providing receipts.

From FY27, that cap rises to $1,000, meaning workers can reduce their taxable income by up to $1,000 from the first dollar of work expenses without keeping a single receipt.

For a worker paying the 32.5% marginal rate, claiming the full $1,000 deduction is worth approximately $325 in tax savings when they lodge their FY27 tax return.

The deduction does not apply to FY26 returns lodged from 1 July 2026. But it does apply to FY27.

What to do with the extra money

A tax cut of $268 per year is not life-changing.

But small, consistent amounts invested over time compound into meaningful outcomes.

An extra $268 per year invested into the share market, earning the historical ASX 200 average of approximately 8.5% per annum, grows to approximately $13,400 over 20 years.

For investors who want to put their tax saving to work immediately, Commonwealth Bank of Australia (ASX: CBA) remains one of the most widely held ASX shares among Australian retail investors. CBA shares offer a fully franked dividend yield and long-term earnings track record that suits a small, consistent investment approach.

Foolish takeaway for your tax bill

Your tax rate dropped on 1 July 2026.

The cut is small, worth up to $268 this year and $536 from 2027. But combined with the new $1,000 instant tax deduction, FY27 is meaningfully less taxing than FY26 was.

The smartest move is to direct that saving somewhere productive rather than letting it disappear into the household budget unnoticed.

The post Your tax rate just dropped. Here is exactly how much more you will take home from 1 July appeared first on The Motley Fool Australia.

More reading

• Forget CBA shares, I’d buy these ASX bank stocks instead
• ASX financials went from the best sector in FY25 to negative growth in FY26. Here’s what changed
• Owned CBA shares for 10 years? Here’s how much money you’ve made
• 2 world-class ASX 200 shares I want in my portfolio
• How much do I need in superannuation to receive $5,500 per month in passive income?

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Sometimes the market focuses heavily on short-term problems and misses the long-term potential of a business. That is where broker research can uncover interesting ASX opportunities.

While analysts can be wrong, their work can highlight businesses where the market may be underestimating future growth.

Three ASX shares that have recently caught my attention are named below.

ResMed Inc. (ASX: RMD)

The first ASX share I would consider buying is one where the market appears to have become much more cautious.

ResMed shares are trading around $31.44, and Morgans believes the recent weakness has created an attractive opportunity.

The concerns are understandable. Investors have been weighing the potential impact of GLP-1 therapies, the possibility of Philips returning to the US PAP market, and broader weakness across healthcare shares.

However, I think the bigger picture remains compelling. ResMed operates in a healthcare market with a huge long-term opportunity. Sleep apnoea and related breathing disorders affect a large number of people globally, and many remain undiagnosed or untreated. That creates a significant runway for growth.

I also like the direction of the business beyond traditional devices. Connected technology, digital health solutions, and software can help improve patient outcomes while making treatment more accessible.

Morgans highlighted that ResMed has de-rated to around 16 times forward earnings, close to its lowest valuation since the post-GFC period, while consensus still expects double-digit earnings growth. For this reason, it has a buy recommendation and $41.72 target price on its shares.

The risks are real, but I think the market may be underestimating the quality of the underlying business.

Flight Centre Travel Group Ltd (ASX: FLT)

The second opportunity comes from a business that has been caught up in broader travel uncertainty.

Flight Centre shares have struggled as investors assess the impact of geopolitical issues and weaker operating conditions.

But I think the long-term travel story remains attractive. People continue to value experiences, holidays, and international travel. When confidence improves, travel demand can recover quickly.

What interests me about Flight Centre is the strength of its position. The company has built a global travel network, strong brand recognition, and a valuable customer base. It also has a strong balance sheet.

Morgans believes the recent weakness creates an opportunity, highlighting the company’s financial strength and the potential for a stronger recovery in the second half of FY27. It has a buy recommendation and $14.80 target price on the shares.

I think the key is patience. The recovery may take time, but if travel conditions normalise, earnings and the share price could respond positively.

Sigma Healthcare Ltd (ASX: SIG)

The final ASX share I would look at is Chemist Warehouse owner Sigma Healthcare.

Ord Minnett believes the company’s UK expansion opportunity could become significant over time. The initial rollout is still small, but the market itself is large and fragmented, creating an opportunity for a proven retail model to expand.

What I find interesting is the possibility of taking existing capabilities into a new market. Sigma has access to pharmacy infrastructure, retail experience, and the backing of one of Australia’s strongest consumer brands through Chemist Warehouse.

There is execution risk, as with any international expansion. But I think the potential upside comes from the ability to replicate a successful model in a much larger market.

Ord Minnett recently placed a buy recommendation and $3.40 target price on the shares. I think this is a fair valuation and shows potential for good returns from its current share price of around $2.82.

Foolish takeaway

I think these three ASX shares are interesting because investors are currently looking beyond the headlines and asking whether the long-term opportunity has changed.

In my view, the businesses themselves still have attractive qualities. The challenge for investors is having the patience to wait for those strengths to become more visible.

The post Why I want to own these ASX shares brokers rate as buys appeared first on The Motley Fool Australia.

More reading

• How to tell if an ASX share is cheap or a value trap
• How should I invest my money in FY27?
• 2 ASX healthcare shares crashing, now bouncing: buy, hold or sell?
• Buy, hold, sell: Dexus, Resmed, BHP shares
• These are the 10 most shorted ASX shares

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Flight Centre Travel Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.